Little Joy L, Wheeler Frances B, Koumenis Constantinos, Kridel Steven J
Department of Cancer Biology, Comprehensive Cancer Center, Wake Forest University School of Medicine, Medical Center Boulevard, Winston-Salem, NC, USA.
Mol Cancer Ther. 2008 Dec;7(12):3816-24. doi: 10.1158/1535-7163.MCT-08-0558.
Fatty acid synthase (FASN) is the terminal enzyme responsible for fatty acid synthesis and is up-regulated in tumors of various origins to facilitate their growth and progression. Because of several reports linking the FASN and proteasome pathways, we asked whether FASN inhibitors could combine with bortezomib, the Food and Drug Administration-approved proteasome inhibitor, to amplify cell death. Indeed, bortezomib treatment augmented suboptimal FASN inhibitor concentrations to reduce clonogenic survival, which was paralleled by an increase in apoptotic markers. Interestingly, FASN inhibitors induced accumulation of ubiquinated proteins and enhanced the effects of bortezomib treatment. In turn, bortezomib increased fatty acid synthesis, suggesting crosstalk between the pathways. We hypothesized that cell death resulting from crosstalk perturbation was mediated by increased unfolded protein response (UPR) signaling. Indeed, disruption of crosstalk activated and saturated the adaptation arm of UPR signaling, including eIF2alpha phosphorylation, activating transcription factor 4 expression, and X-box-binding protein 1 splicing. Furthermore, although single agents did not activate the alarm phase of the UPR, crosstalk interruption resulted in activated c-Jun NH2-terminal kinase and C/EBP homologous protein-dependent cell death. Combined, the data support the concept that the UPR balance between adaptive to stress signaling can be exploited to mediate increased cell death and suggests novel applications of FASN inhibitors for clinical use.
脂肪酸合酶(FASN)是负责脂肪酸合成的末端酶,在各种起源的肿瘤中上调,以促进其生长和进展。由于有几份报告将FASN与蛋白酶体途径联系起来,我们询问FASN抑制剂是否可以与美国食品药品监督管理局批准的蛋白酶体抑制剂硼替佐米联合使用,以增强细胞死亡。事实上,硼替佐米治疗可增强次优浓度的FASN抑制剂降低克隆形成存活率的作用,同时凋亡标志物增加。有趣的是,FASN抑制剂诱导泛素化蛋白积累,并增强硼替佐米治疗的效果。反过来,硼替佐米增加脂肪酸合成,表明这两条途径之间存在相互作用。我们假设,相互作用扰动导致的细胞死亡是由未折叠蛋白反应(UPR)信号增强介导的。事实上,相互作用的破坏激活并饱和了UPR信号的适应臂,包括eIF2α磷酸化、激活转录因子4表达和X盒结合蛋白1剪接。此外,虽然单一药物不会激活UPR的警报阶段,但相互作用的中断会导致c-Jun NH2末端激酶和C/EBP同源蛋白依赖性细胞死亡。综合来看,这些数据支持这样一种概念,即可以利用UPR在适应应激信号之间的平衡来介导细胞死亡增加,并提示FASN抑制剂在临床应用中的新用途。